Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis

Fredrik Schjesvold,[1] Paul G. Richardson,[2] Thierry Facon,[3] Adrián Alegre,[4] Andrew Spencer,[5] Artur Jurczyszyn,[6] Kazutaka Sunami,[7] Laurent Frenzel,[8] Chang-Ki Min,[9] Sophie Guillonneau,[10] Peggy L. Lin,[11] Solenn Le-Guennec,[12] Frank Campana,[13] Helgi van de Velde,[13] Samira Bensfia[11] and Sara Bringhen[14]

[1]Oslo Myeloma Center, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway; [2]Dana-Farber Cancer Institute, Boston, MA, USA; [3]Lille University Hospital, Lille, France; [4]Hospital Universitario La Princesa & Hospital Quironsalud, Madrid, Spain; [5]Department of Clinical Hematology, Alfred Health-Monash University, Melbourne, Australia; [6]Department of Hematology, Jagiellonian University Medical College, Krakow, Poland; [7]Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan; [8]Hôpital Necker-Enfants Malades, Paris, France; [9]Department of Hematology, Catholic Hematology Hospital and Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of South Korea; [10]Sanofi CMO, Chilly-Mazarin, France; [11]Sanofi Global Oncology, Cambridge, MA, USA; [12]Sanofi R&D, Vitry-sur-Seine, France; [13]Sanofi R&D, Cambridge, MA, USA and [14]Myeloma Unit, Division of Hematology, University of Torino, Azienda-Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy

Correspondence: SARA BRINGHEN - sarabringhen@yahoo.com

Published in Haematologica 2021;106(4):1182-1187

doi:10.3324/haematol.2021.279160

In the article by Schjesvold *et al*., entitled "Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis", which appeared in the April 2021 issue of *Haematologica* (volume 106, pages 1182-1187), the values entered for "Refractory status" at the bottom of Table 1 were incorrect. The authors have prepared a new, corrected version of Table 1, which is reported here. The authors apologize to the Editor and readers for their mistake. They want to underscore that the results and conclusions of the paper are unaffected by the error.

Table 1. Patients' baseline characteristics at study entry by age group in the intent-to-treat population.

	≥75 years (n=61)		65–74 years (n=122)		<65 years (n=124)	
	Isa-Pd (n=32)	Pd (n=29)	Isa-Pd (n=68)	Pd (n=54)	Isa-Pd (n=54)	Pd (n=70)
Age (years)						
Mean (SD)	77.9 (2.0)	78.3 (3.2)	69.4 (2.9)	69.0 (2.5)	56.5 (5.9)	57.0 (6.1)
Median (range)	77 (75-83)	78 (75-86)	69 (65-74)	69 (65-74)	57.5 (36-64)	58 (41-64)
MM subtype, n (%)						
IgG	21 (65.6)	22 (75.9)	45 (66.2)	32 (59.3)	38 (70.4)	47 (67.1)
IgA	9 (28.1)	4 (13.8)	17 (25.0)	19 (35.2)	7 (13.0)	18 (25.7)
IgM	0	0	1 (1.5)	0	1 (1.9)	0
Kappa light chain only	1 (3.1)	2 (6.9)	2 (2.9)	1 (1.9)	5 (9.3)	4 (5.7)
Lambda light chain only	1 (3.1)	1 (3.4)	3 (4.4)	2 (3.7)	3 (5.6)	1 (1.4)
ISS stage*, n (%)						
Stage I	7 (21.9)	4 (13.8)	31 (45.6)	18 (33.3)	26 (48.1)	29 (41 .4)
Stage II	12 (37.5)	12 (41.4)	22 (32.4)	23 (42.6)	19 (35.2)	21 (30.0)
Stage III	13 (40.6)	12 (41.4)	14 (20.6)	13 (24.1)	7 (13.0)	18 (25.7)
Unknown	0	1 (3.4)	1 (1.5)	0	2 (3.7)	2 (2.9)
ECOG Performance Status, n (%)						
0	9 (28.1)	14 (48.3)	24 (35.3)	18 (33.3)	22 (40.7)	37 (52.9)
1	18 (56.3)	8 (27.6)	36 (52.9)	31 (57.4)	29 (53.7)	29 (41.4)
2	5 (15.6)	7 (24.1)	8 (11.8)	5 (9.3)	3 (5.6)	4 (5.7)
Cytogenetic risk†, n (%)						
High-risk CA	7 (21.9)	11 (37.9)	9 (13.2)	6 (11.1)	8 (14.8)	19 (27.1)
Standard-risk CA	20 (62.5)	9 (31.0)	47 (69.1)	32 (59.3)	36 (66.7)	37 (52.9)
Unknown or missing	5 (15.6)	9 (31.0)	12 (17.6)	16 (29.6)	10 (18.5)	14 (20.0)
N. of patients with a medical history of Asthma or COPD, n (%)	5 (15.6)	5 (17.2)	7 (10.3)	8 (14.8)	4 (7.4)	4 (5.7)
N. of patients with renal impairment‡, n (%)	30 (93.8)	27 (93.1)	63 (92.6)	51 (94.4)	49 (90.7)	67 (95.7)
eGFR, n (%)						
≥60-<90 mL/min/1.73 m² (mild impairment)	10 (33.3)	11 (40.7)	31 (49.2)	25 (49.0)	20 (40.8)	33 (49.3)
≥45-<60 mL/min/1.73 m²	13 (43.3)	9 (33.3)	14 (22.2)	12 (23.5)	8 (16.3)	11 (16.4)
≥30-<45 mL/min/1.73 m²	6 (20.0)	5 (18.5)	7 (11.1)	4 (7.8)	6 (12.2)	7 (10.4)
≥15-<30 mL/min/1.73 m² (severe impairment)	0	1 (3.7)	0	0	1 (2.0)	0
N. of prior lines of therapy, Median (range)	3 (2–11)	3 (2–10)	3 (2–8)	3 (2–6)	3 (2–10)	3 (2–7)
Prior therapy, n (%)						
Alkylating agent	27 (84.4)	29 (100)	60 (88.2)	51 (94.4)	52 (96.3)	68 (97.1)
Proteasome inhibitor	32 (100)	29 (100)	68 (100)	54 (100)	54 (100)	70 (100)
Lenalidomide	32 (100)	29 (100)	68 (100)	54 (100)	54 (100)	70 (100)
Refractory status, n (%)						
Lenalidomide refractory	30 (93.8)	28 (96.6)	63 (92.6)	47 (87.0)	51 (94.4)	65 (92.9)
PI refractory	25 (78.1)	21 (72.4)	54 (79.4)	41 (75.9)	39 (72.2)	53 (75.7)
Lenalidomide and PI refractory	24 (75.0)	20 (69.0)	50 (73.5)	37 (68.5)	37 (68.5)	50 (71.4)

*International Staging System staging was derived based on the combination of serum β_2-microglobulin and albumin concentrations. †High risk chromosomal abnormalities were defined as the presence of del(17p), and/or t(4;14), and/or t(14;16) by fluorescence *in situ* hybridization. Cytogenetics was performed by a central laboratory with a cut-off of analyzed plasma cells of 50% for del(17p), and of 30% for t(4;14) and t(14;16). ‡Renal impairment was defined as an estimated glomerular filtration rate <60 mL/min/1.73 m² as determined using the Modification of Diet in Renal Disease (MDRD) equation. Isa: isatuximab: Pd: pomalidine and dexamethasone; SD: standard deviation; MM: multiple myeloma; Ig: immunoglobulin; ISS: International Staging System; ECOG: Eastern Cooperative Oncology Group; CA: chromosomal abnormalities; COPD: chronic obstructive pulmonary disease; eGFR: estimated glomerular filtration rate; PI: proteasome inhibitor.